Home > Knowledge > Content
Biotech drug development in China: the lack of property rights and incentives
Aug 23, 2016

On January 7, the biological industry development plan, issued by the State Council, pointed out that from 2013 to 2015, the biomedical industry output value of annual growth of more than 20%, promoting a number of new drugs with independent intellectual property rights on the market, form which the annual output value exceeding tens of billions worth of business.


Only 21 days zhihou, by China foreign investment enterprise Association drug development and development industry Committee (RDPAC) and United States global biological technology industrial organization (BIO) research half released of a copies name for in China build world leading of innovation type biological technology drug industry of report obtained of conclusion for: in China, near five years to biological drug of share has been stay in 5% around, development urgently speed.


Great expectations for bio-pharmaceutical industry on the one hand, the Government has "Eleven-Five" began during a huge investment on the other, failed to break through and substantive development of the industry, what is the problem?


Long-term studies of biotechnology drugs experts answer is, because of the lack of protection for intellectual property rights and incentives, lack the necessary impetus to the development of industrial development, and medical needs of the biotech drugs also inhibited to some extent.


Subscribe to our email list
Sign up with your name and email to get the latest proway updates, exclusive access to promotions, sales events, pre-order sales & more!
Connect with Sundent Pharm Group
Become our fan, follow us & subscribe for the latest updates and deals
QR Code
  • About Us
  • Products
  • News
  • Knowledge
  • Contact Us
  • Feedback
  • Copyright © Sundent Pharm Group All rights reserved.